Mitochondrial disorder firm Mitobridge was purchased by Astellas Pharma in an amended 2013 deal for $225 million upfront and up to another $225 million in milestones. Mitobridge has an ongoing early-stage study of MA-0211 for patients with Duchenne muscular dystrophy and a preclinical program for mitochondrial myopathies and fatty acid oxidation disorders.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.